Rosuvastatin (Crestor) and SLCO1B1/ABCG2 Pharmacogenomics

What Is Rosuvastatin?

Rosuvastatin (brand name Crestor) is one of the most potent statin medications available, widely prescribed for hypercholesterolemia and cardiovascular risk reduction. Like other statins, it works by inhibiting HMG-CoA reductase, but rosuvastatin achieves greater LDL reduction at lower doses compared to many alternatives.

Unlike simvastatin, rosuvastatin is minimally metabolized by CYP enzymes. Its pharmacogenomic profile is instead driven by two transporter genes: SLCO1B1, which controls hepatic uptake, and ABCG2, which controls intestinal absorption. This dual-gene interaction makes rosuvastatin unique among statins from a pharmacogenomics perspective.

Why Rosuvastatin Response Involves Two Genes

Rosuvastatin exposure is shaped by two independent transporter mechanisms. First, SLCO1B1 encodes the OATP1B1 transporter, which moves rosuvastatin from the bloodstream into liver cells — where it exerts its cholesterol-lowering effect. The rs4149056 C allele reduces OATP1B1 function, impairing hepatic uptake and raising circulating drug levels.

Second, ABCG2 encodes the BCRP (Breast Cancer Resistance Protein) efflux transporter in the intestinal wall. BCRP normally pumps rosuvastatin back into the gut lumen, limiting how much is absorbed. The rs2231142 A allele reduces BCRP function, leading to increased intestinal absorption.

The combined effect is clinically significant: a patient carrying variants in both genes may have both increased absorption from the gut AND reduced clearance into the liver, resulting in substantially higher plasma rosuvastatin levels. This two-gene dynamic is central to understanding how pharmacogenomic testing applies to rosuvastatin prescribing.

SLCO1B1 and Rosuvastatin

SLCO1B1 affects rosuvastatin through the same hepatic uptake mechanism that drives simvastatin myopathy risk. The key variant is rs4149056, with three functional categories:

• Normal Function (TT at rs4149056): Standard OATP1B1 transporter activity. Rosuvastatin is efficiently taken up into liver cells. Standard prescribing applies.
• Intermediate Function (TC): One reduced-function allele. Moderately elevated circulating rosuvastatin levels. CPIC recommends considering dose adjustment.
• Poor Function (CC): Two reduced-function alleles. Substantially elevated rosuvastatin levels. Strongest case for dose reduction based on SLCO1B1 alone.

Rosuvastatin generally carries lower myopathy risk than simvastatin at equivalent cholesterol-lowering effect, but SLCO1B1 reduced function is still clinically relevant for dose optimization. For simvastatin, SLCO1B1 has even stronger clinical impact — see our simvastatin page.

ABCG2 and Rosuvastatin Absorption

ABCG2 encodes the BCRP efflux transporter, which is expressed in the intestinal epithelium and limits oral absorption of rosuvastatin. The key variant is rs2231142 — the A allele (also reported as 421C>A or Q141K) produces a reduced-function BCRP transporter.

Individuals homozygous for the reduced-function allele (AA genotype at rs2231142) show approximately 2-fold higher rosuvastatin exposure compared to those with normal BCRP function. Heterozygous carriers (CA) have an intermediate effect. CPIC recommends considering a lower starting dose for patients with reduced ABCG2 function.

Importantly, ABCG2 does not significantly affect simvastatin pharmacokinetics. This is a key differentiator: the ABCG2 interaction is clinically relevant for rosuvastatin but not for simvastatin, which is why rosuvastatin requires a two-gene analysis.

CPIC Guideline Summary

Rosuvastatin dosing guidance considers the combined effect of both SLCO1B1 and ABCG2 genotypes. The general framework:

• Both Normal Function: Standard rosuvastatin prescribing. No genotype-based adjustments needed.
• SLCO1B1 Reduced Function: Consider a lower rosuvastatin dose due to reduced hepatic uptake and elevated circulating levels.
• ABCG2 Reduced Function: Consider a lower starting dose due to increased intestinal absorption and higher plasma exposure.
• Both Reduced Function: Strongest case for dose reduction or enhanced monitoring. Combined effect of increased absorption and reduced hepatic clearance may substantially elevate rosuvastatin levels.

As with all pharmacogenomic guidance, genotype is one factor among several. Dose selection also depends on the target LDL goal, renal function, concomitant medications, and patient tolerance.

Clinical Context

The role of ABCG2 in rosuvastatin pharmacokinetics was established through genome-wide association studies. Keskitalo et al. (2009; PMID: 19262612) demonstrated that the ABCG2 rs2231142 variant significantly increases rosuvastatin plasma concentrations, with the effect being specific to rosuvastatin among the statins studied.

SLCO1B1 evidence for rosuvastatin builds on the broader statin transporter literature, including the pivotal SEARCH trial findings for simvastatin. While the myopathy risk gradient is less steep for rosuvastatin than for simvastatin, the pharmacokinetic impact of SLCO1B1 variants on rosuvastatin clearance is well-documented across multiple clinical studies.

Understanding Your Results

If you have raw DNA data from 23andMe, AncestryDNA, or another consumer service, DecodeMyBio can determine your genotype at both SLCO1B1 and ABCG2 and report whether rosuvastatin is flagged as a drug-gene interaction. Your Medication Safety Report shows both genotypes, function categories, and the combined CPIC-informed recommendation — a two-gene analysis that reflects the unique pharmacogenomic profile of rosuvastatin.

You can view a sample report to see the format. If your report identifies reduced function at either or both genes, this does not mean you should stop rosuvastatin — it may inform dose optimization or monitoring discussions with your healthcare provider. Always review results in clinical context. See our limitations page for important context about consumer-grade analysis.

Related Resources

• SLCO1B1 gene — variants, phenotypes, and statin transport
• Simvastatin and SLCO1B1 — single-gene statin interaction
• Warfarin and CYP2C9/VKORC1 — another multi-gene pharmacogenomic interaction
• What to do with your 23andMe raw data

Frequently Asked Questions